Wang Wenjun, Liu Tianlong, Zhang Yi
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Clinical Pharmacy, The 940th Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou, China.
Digit Health. 2023 Apr 18;9:20552076231169846. doi: 10.1177/20552076231169846. eCollection 2023 Jan-Dec.
As a neuroprotective agent, ellagic acid (EA) is extremely beneficial. Our previous study found that EA can alleviate sleep deprivation (SD)-induced abnormal behaviors, although the mechanisms underlying this protective effect have not yet been fully elucidated.
An integrated network pharmacology and targeted metabolomics approach was utilized in this study to investigate the mechanism of EA against SD-induced memory impairment and anxiety.
Behavioral tests were conducted on mice after 72 h of SD. Hematoxylin and eosin staining and nissl staining were then carried out. Integration of network pharmacology and targeted metabolomics was performed. Eventually, the putative targets were further verified using molecular docking analyses and immunoblotting assays.
The present study findings confirmed that EA ameliorated the behavioral abnormalities induced by SD and prevented histopathological and morphological damage to hippocampal neurons. Through multivariate analysis, clear clustering was obtained among different groups, and potential biomarkers were identified. Four key targets, catechol--methyltransferase (COMT), cytochrome P450 1B1 (CYP1B1), glutathione S-transferase A2 (GSTA2), and glutathione S-transferase P1 (GSTP1), as well as the related potential metabolites and metabolic pathways, were determined by further integrated analysis. Meanwhile, in-silico studies revealed that EA is well located inside the binding site of CYP1B1 and COMT. The experimental results further demonstrated that EA significantly reduced the increased expression of CYP1B1 and COMT caused by SD.
The findings of this study extended our understanding of the underlying mechanisms by which EA treats SD-induced memory impairment and anxiety, and suggested a novel approach to address the increased health risks associated with sleep loss.
作为一种神经保护剂,鞣花酸(EA)极其有益。我们之前的研究发现,EA可以减轻睡眠剥夺(SD)诱导的异常行为,尽管这种保护作用的潜在机制尚未完全阐明。
本研究采用综合网络药理学和靶向代谢组学方法,探讨EA对抗SD诱导的记忆损伤和焦虑的机制。
对经历72小时SD的小鼠进行行为测试。然后进行苏木精-伊红染色和尼氏染色。进行网络药理学和靶向代谢组学的整合。最终,使用分子对接分析和免疫印迹分析进一步验证推定的靶点。
本研究结果证实,EA改善了SD诱导的行为异常,并预防了海马神经元的组织病理学和形态学损伤。通过多变量分析,不同组之间获得了清晰的聚类,并鉴定了潜在的生物标志物。通过进一步的综合分析,确定了四个关键靶点,儿茶酚-O-甲基转移酶(COMT)、细胞色素P450 1B1(CYP1B1)、谷胱甘肽S-转移酶A2(GSTA2)和谷胱甘肽S-转移酶P1(GSTP1),以及相关的潜在代谢物和代谢途径。同时,计算机模拟研究表明,EA很好地位于CYP1B1和COMT的结合位点内。实验结果进一步证明,EA显著降低了SD引起的CYP1B1和COMT表达增加。
本研究结果扩展了我们对EA治疗SD诱导的记忆损伤和焦虑的潜在机制的理解,并提出了一种新的方法来应对与睡眠不足相关的健康风险增加问题。